Neurocrine Biosciences NBIX Cash Flow Statement (2010-2026)

NASDAQ NBIX
$141.31 -0.69 (-0.49%)
At close: Oct 21, 2026 · 4:00 PM EDT
Reported Financials

Neurocrine Biosciences Quarterly Cash Flow Statement

Periods 65 quarters
Latest Jun 2026

Neurocrine Biosciences reported cash from operations of $136.40M and free cash flow of $128.60M for the quarter ended Jun 2026, up 33.7% year over year. This cash flow statement covers 65 quarters of results from Jun 2010 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
22.50M-7.30M13.90M-16.90M68.50M89.00M-76.60M95.50M83.10M147.70M43.40M65.00M129.80M103.10M7.90M107.50M209.50M153.70M197.90M144.40M
Depreciation and DepletionDep. & Depletion
2.80M3.00M3.30M3.90M4.00M3.90M4.10M4.20M4.60M4.90M5.30M6.40M5.60M6.20M6.60M6.30M6.70M6.40M7.20M8.40M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.50M0.90M0.90M0.90M0.80M0.90M0.90M0.90M0.90M1.00M1.00M1.00M1.10M0.10M16.40M
Amortization of Deferred ChargesAmort. Deferred Charges
4.20M4.10M0.40M0.40M0.20M0.20M0.20M0.20M0.20M0.10M
Depreciation & Amortization (CF)Dep. & Amort.
2.80M3.00M3.30M3.90M4.00M3.90M4.10M4.20M4.60M4.90M5.30M6.40M5.60M6.20M6.60M6.30M6.70M6.40M7.20M8.40M
Share-based CompensationStock Comp.
37.10M35.60M37.00M49.50M43.10M43.50M39.90M68.50M47.80M38.10M44.50M43.10M41.50M66.40M52.80M52.80M53.70M58.60M57.20M65.00M
Deferred Taxes
5.70M-4.70M-0.30M-3.10M9.00M13.50M-31.60M-41.50M-4.20M20.60M-15.60M-41.30M-34.90M-31.30M-13.70M-37.40M168.30M48.20M-61.10M-25.30M
Gains from Sales and DivestituresGains Divest
28.60M
Gains from Investment SecuritiesGains Investment
-8.20M28.40M19.90M-7.40M11.10M7.20M2.20M37.30M-40.10M29.00M1.60M-19.90M-16.90M-1.90M-30.60M-6.70M30.60M2.70M25.30M1.20M
Other non-cash itemsOther Non-Cash
70.00M-0.90M0.30M6.50M7.20M7.10M6.60M5.90M2.70M3.90M
Change in Working Capital
Change in ReceivablesChange Receivables
5.30M21.70M78.00M15.50M22.20M46.50M41.70M-4.20M30.40M21.40M11.30M17.60M12.90M-2.00M36.90M79.70M132.30M-38.40M81.40M84.30M
Change in InventoryChange Inventory
-2.80M5.00M-1.50M0.30M7.70M-3.90M-1.80M-1.60M-2.90M0.90M-1.10M5.30M3.30M11.60M1.70M-2.10M12.30M3.40M-4.30M6.50M
Change in Accured ExpensesChange Accured Exp.
8.70M19.10M11.50M32.70M32.80M37.60M6.70M16.20M124.40M-98.30M-18.60M-59.50M44.20M77.30M-3.00M15.10M71.60M76.50M-14.30M-8.50M
Change in TaxesChange Taxes
55.10M15.40M0.40M-70.10M35.50M119.80M-59.60M
Change in Other Operating AssetsOther Assets Change
Change in Other Operating LiabilitiesOther Liabilities Change
Other Working Capital ChangesOther WC Changes
-27.20M12.50M-10.70M8.50M-18.50M3.50M-24.30M71.40M-50.90M-24.70M-2.80M-3.90M-18.80M-28.50M2.50M23.00M-42.10M-27.80M-31.40M78.80M
Other Operating ActivitiesOther Ops.
2.10M-10.70M0.80M1.50M0.70M-1.40M-0.10M-0.20M-0.30M1.30M3.40M-3.40M0.10M0.70M0.50M-0.50M
Cash from OperationsCash from Ops.
61.80M4.20M-40.50M138.10M98.80M143.00M-125.20M179.60M212.00M123.50M130.30M64.60M158.00M242.50M64.80M102.00M227.50M388.40M145.80M136.40M
Investing Activities
Capital ExpendituresCapex
5.70M8.90M7.60M8.80M-1.70M1.80M8.50M6.80M7.60M5.40M11.20M11.60M8.10M7.30M10.70M12.50M13.20M-2.40M9.10M7.80M
Sales of Property, Plant and EquipmentPP&E (Sale)
Change in Property, Plant and EquipmentChange in PP&E
-5.70M-8.90M-7.60M-8.80M1.70M-1.80M-8.50M-6.80M-7.60M-5.40M-11.20M-11.60M-8.10M-7.30M-10.70M-12.50M-13.20M2.40M-9.10M-7.80M
Divestments
63.20M
Net of Acquisitions & DivestmentsNet Acquisitions
63.20M
Purchase of InvestmentsInvestments Purchased
280.20M141.40M200.50M60.90M134.20M233.30M237.50M323.80M362.70M487.20M320.10M191.70M232.50M311.80M273.20M315.10M408.50M323.00M819.50M37.40M
Sale and Maturity of InvestmentsInvestments Sold
159.70M174.00M176.50M101.10M71.20M162.20M203.90M204.70M273.00M290.80M276.30M175.10M265.30M250.80M298.10M298.60M225.00M267.70M259.20M2,268.30M
Other Investing ActivitiesOther investing
Cash from Investing ActivitiesCash from Investing
-126.20M23.70M-31.60M31.40M-61.30M-115.60M-42.10M-125.90M-97.30M-201.80M-55.00M-28.20M24.70M-68.30M14.20M-29.00M-196.70M-52.90M-506.20M-135.40M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt RepaymentsLT Debt Repayment
279.00M
Non-Current Debt
-279.00M
Net Debt Issuances and RepaymentsNet Debt Issuance
-279.00M
Change in Capital Stock
Common Stock IssuedStock Issued
7.50M1.80M6.10M2.60M11.40M24.60M8.20M2.90M18.80M35.40M69.90M15.80M26.40M10.00M32.10M14.40M45.60M37.30M23.60M84.80M
Shares Repurchased
300.00M150.00M17.70M54.00M12.00M
Net Shares Issued and RepurchasedNet Shares Issued
7.50M1.80M6.10M2.60M11.40M24.60M8.20M2.90M18.80M35.40M69.90M15.80M26.40M-290.00M-117.90M-3.30M45.60M37.30M-30.40M72.80M
Net Equity Issued and RepurchasedNet Equity Issued
7.50M1.80M6.10M2.60M11.40M24.60M8.20M2.90M18.80M35.40M69.90M15.80M26.40M-290.00M-117.90M-3.30M45.60M37.30M-30.40M72.80M
Other financing activitiesOther financing
-55.70M-9.40M
Cash from Financing ActivitiesCash from Financing
7.50M1.80M6.10M-276.40M11.40M24.60M8.20M2.90M18.80M35.40M69.90M-293.00M26.40M-290.00M-117.90M-3.30M45.60M37.30M-86.10M63.40M
Additional items
Exchange Rate EffectFX Effect
0.30M0.30M-0.30M-0.20M
Change in Cash
-56.90M29.70M-66.00M-106.90M48.90M50.70M-159.10M56.60M133.50M-42.60M145.20M-256.60M209.40M-116.10M-38.90M69.90M76.20M372.80M-446.50M64.40M
Ending Cash Balance
314.30M344.00M278.00M171.10M220.00M270.70M111.60M168.20M301.70M259.10M404.30M147.70M357.10M241.00M202.10M272.00M348.20M721.00M274.50M338.90M
Free Cash FlowFCF
56.10M-4.70M-48.10M129.30M100.50M141.20M-133.70M172.80M204.40M118.10M119.10M53.00M149.90M235.20M54.10M89.50M214.30M390.80M136.70M128.60M
Net Cash FlowNCF
-56.90M29.70M-66.00M-106.90M48.90M52.00M-159.10M56.60M133.50M-42.90M145.20M-256.60M209.10M-115.80M-38.90M69.70M76.40M372.80M-446.50M64.40M
Interest Paid
4.30M2.00M1.90M
Income Taxes PaidTaxes Paid
1.80M1.70M3.10M1.20M10.10M0.20M3.20M1.60M46.50M0.20M92.60M51.70M73.00M0.60M71.90M1.10M7.80M0.30M

Neurocrine Biosciences Cash Flow Statement API

Pull Neurocrine Biosciences's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=NBIX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY